Clinical trials: Advanced Malignant Tumor
Non Small Cell Lung Cancer
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people…
- Trial name
- NCT00347412
- Testing
- Paclitaxel, NOV-002, Carboplatin
- Where
- 75 sites in United States, Canada and 10 more
- Volunteers
- 903 people
- Sponsor
- Cellectar Biosciences, Inc.
Solid Tumor (Phase I)
This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.
The Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of BD200 in adult participants with advanced solid cancers.
- Trial name
- NCT07797907
- Testing
- BD200
- Volunteers
- 110 people
- Sponsor
- Biolojic Design Ltd.
Advanced Solid Tumor
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
This is a study to evaluate the safety and tolerability of the study drug HBM1020 which contains two parts. Part 1 will enroll solid tumor participants and Part 2 will enroll renal cell carcinoma (RCC) and colorectal…
- Trial name
- NCT05824663
- Testing
- HBM1020
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Harbour BioMed US, Inc.
Advanced Solid Tumor
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06112704
- Testing
- HS-20093
- Where
- 21 sites in China
- Volunteers
- 220 people
- Sponsor
- Hansoh BioMedical R&D Company
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Lung Cancer, Solid Tumor (Not Breast or Prostate Cancers)
Cabozantinib in Advanced Solid Malignancies
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01588821
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Solid Tumor
Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors
This is a molecular epidemiological investigation aiming to identify microsatellite instability status from circulating tumor DNA in Chinese patients with refractory advanced solid tumors.
- Trial name
- IMPACT (NCT03596593)
- Testing
- SPANOM (identifying MSI status from ctDNA)
- Where
- China
- Volunteers
- 8,000 people
- Sponsor
- Peking University
Solid Tumor
A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.
- Trial name
- NCT02414516
- Testing
- OBP-801
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Oncolys BioPharma Inc
Cancer, Tumor, Solid
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805…
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
- Trial name
- NCT05094804
- Testing
- OR2805, Cemiplimab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 172 people
- Sponsor
- OncoResponse, Inc.
Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor
CREATE: Cross-tumoral Phase 2 With Crizotinib
The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways.
- Conditions
- Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma
- Trial name
- CREATE (NCT01524926)
- Testing
- Crizotinib (PF-02341066)
- Where
- 25 sites in Belgium, France and 8 more
- Volunteers
- 582 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Solid Tumor, Adult
A Study of HMPL-453 in Patients With Advanced Solid Malignancies
This is a dose escalation study consisting of two stages: Dose-escalation stage (stage 1): Patients will take a single dose of HMPL-453 on Day 1 and will be followed for one week for safety observations.
- Trial name
- NCT03160833
- Testing
- HMPL-453
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Hutchison Medipharma Limited
Advanced Solid Tumor
Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor
The growth and metastasis of solid tumors are dependent on angiogenesis. Endostatin, the C-terminal proteolytic fragment of collagen XVIII, is an effective endogenous angiogenesis inhibitor in cancer therapy in mice.
- Trial name
- NCT00262327
- Testing
- Antangiogenesis, endostatin gene
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
Melanoma, Non Small Cell Lung Cancer
Dabrafenib and/or Trametinib Rollover Study
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
- Trial name
- NCT03340506
- Testing
- dabrafenib, trametinib
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Study BP29541 is a first-in-human, open-label, multi-center, dose-escalation Phase I clinical study of single-agent RO6958688 in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA) positive solid…
- Trial name
- NCT02324257
- Testing
- RO6958688, Obinutuzumab, Tocilizumab
- Where
- 21 sites in United States, Canada and 5 more
- Volunteers
- 149 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
This is a Phase 1 open-label, dose-escalation, safety and pharmacokinetic study of rucaparib administered twice daily (BID) to Japanese patients with a solid tumor who have failed previous standard treatment for their cancer.
- Trial name
- NCT03499444
- Testing
- Rucaparib
- Where
- 3 sites in Japan
- Volunteers
- 29 people
- Sponsor
- pharmaand GmbH
Solid Tumor, Pancreatic Adenocarcinoma
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.
- Trial name
- NCT03592264
- Testing
- OBI-3424
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- OBI Pharma, Inc
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma
- Trial name
- NCT03233204
- Testing
- Olaparib
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, C-Met Mutation-Related Tumors
Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161
Safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy evaluation of the selective c-MET inhibitor GST-HG161 in patients with advanced or metastatic solid tumors: An open, single and multiple…
- Trial name
- NCT04228406
- Testing
- GST-HG161
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.